Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

A pathway to keep all lifelong learners up to date: the ERS continuing professional development programme.

Farr A, Aliberti S, Loukides S, Massard G, Primhak R, Rohde GGU, Tabin N, Pannetier C, Stolz D.

Eur Respir J. 2020 Feb 27;55(2). pii: 1902425. doi: 10.1183/13993003.02425-2019. Print 2020 Feb. No abstract available.

PMID:
32108083
2.

Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?

Tsilogianni Z, Baker JR, Papaporfyriou A, Papaioannou AI, Papathanasiou E, Koulouris NG, Daly L, Ito K, Hillas G, Papiris S, Bakakos P, Loukides S.

J Clin Med. 2020 Feb 9;9(2). pii: E473. doi: 10.3390/jcm9020473.

3.

ERS and tobacco harm reduction.

Pisinger C, Dagli E, Filippidis FT, Hedman L, Janson C, Loukides S, Ravara S, Saraiva I, Vestbo J; ERS Tobacco Control Committee, on behalf of the ERS.

Eur Respir J. 2019 Dec 4;54(6). pii: 1902009. doi: 10.1183/13993003.02009-2019. Print 2019 Dec. No abstract available. Erratum in: Eur Respir J. 2020 Jan 30;55(1):.

PMID:
31801824
4.

ERS Presidential Summit 2018: multimorbidities and the ageing population.

Gaga M, Powell P, Almagro M, Tsiligianni I, Loukides S, Roca J, Cullen M, Simonds AK, Ward B, Saraiva I, Troosters T, Robalo Cordeiro C.

ERJ Open Res. 2019 Sep 25;5(3). pii: 00126-2019. doi: 10.1183/23120541.00126-2019. eCollection 2019 Jul. Review.

5.

New paradigm in asthma management: switching between biologics!

Mukherjee M, Bakakos P, Loukides S.

Allergy. 2019 Sep 8. doi: 10.1111/all.14038. [Epub ahead of print]

PMID:
31494955
6.

Severe Eosinophilic Asthma.

Bakakos A, Loukides S, Bakakos P.

J Clin Med. 2019 Sep 2;8(9). pii: E1375. doi: 10.3390/jcm8091375. Review.

7.

Diagnostic accuracy of T2 biomarkers for the prediction of airway eosinophilia in treated smoking asthmatic patients with loss of asthma control.

Papathanasiou E, Bakakos P, Hillas G, Ntontsi P, Blizou M, Kostikas K, Koulouris N, Papiris S, Loukides S.

J Allergy Clin Immunol Pract. 2020 Jan;8(1):385-387.e2. doi: 10.1016/j.jaip.2019.05.052. Epub 2019 Jun 13. No abstract available.

PMID:
31257188
8.

Asthma-chronic obstructive pulmonary disease overlap: Diagnostic stability and inflammatory characteristics.

Patentalakis G, Bakakos P, Papaporfyriou A, Papatheodorou G, Hillas G, Kostikas K, Papiris S, Koulouris N, Loukides S.

Allergy. 2019 Nov;74(11):2271-2273. doi: 10.1111/all.13865. Epub 2019 May 28. No abstract available.

PMID:
31077386
9.

Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018.

Seys SF, Quirce S, Agache I, Akdis CA, Alvaro-Lozano M, Antolín-Amérigo D, Bjermer L, Bobolea I, Bonini M, Bossios A, Brinkman P, Bush A, Calderon M, Canonica W, Chanez P, Couto M, Davila I, Del Giacco S, Del Pozo V, Erjefält JS, Gevaert P, Hagedoorn P, G Heaney L, Heffler E, Hellings PW, Jutel M, Kalayci O, Kurowski MM, Loukides S, Nair P, Palomares O, Polverino E, Sanchez-Garcia S, Sastre J, Schwarze J, Spanevello A, Ulrik CS, Usmani O, Van den Berge M, Vasakova M, Vijverberg S, Diamant Z.

Allergy. 2019 Nov;74(11):2244-2248. doi: 10.1111/all.13843. Epub 2019 May 31. No abstract available.

PMID:
31021446
10.

The Economic Burden of Asthma in Greece: A Cross-Sectional Study.

Vellopoulou K, Bakakos P, Loukides S, Maniadakis N, Kourlaba G.

Appl Health Econ Health Policy. 2019 Oct;17(5):629-640. doi: 10.1007/s40258-019-00469-4.

PMID:
30997609
11.

Inflammatory profile in optimally treated patients with adult versus early-onset asthma.

Papaporfyriou A, Papaioannou AI, Hillas G, Konstantelou E, Tseliou E, Koulouris N, Papiris S, Bakakos P, Kostikas K, Loukides S.

Postgrad Med. 2019 Jun;131(5):324-329. doi: 10.1080/00325481.2019.1600884. Epub 2019 Apr 4.

PMID:
30920326
12.

Experimental and investigational phosphodiesterase inhibitors in development for asthma.

Ntontsi P, Detta A, Bakakos P, Loukides S, Hillas G.

Expert Opin Investig Drugs. 2019 Mar;28(3):261-266. doi: 10.1080/13543784.2019.1571582. Epub 2019 Jan 24. Review.

PMID:
30678501
13.

Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.

Price DB, Yang S, Ming SWY, Hardjojo A, Cabrera C, Papaioannou AI, Loukides S, Kritikos V, Bosnic-Anticevich SZ, Carter V, Dorinsky PM.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 13;13:3937-3946. doi: 10.2147/COPD.S174371. eCollection 2018.

14.

Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits.

Papaioannou AI, Diamant Z, Bakakos P, Loukides S.

Respir Med. 2018 Sep;142:15-22. doi: 10.1016/j.rmed.2018.07.006. Epub 2018 Jul 17. Review.

PMID:
30170796
15.

Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?

Papaioannou AI, Loukides S, Kostikas K.

EBioMedicine. 2018 Sep;35:6-7. doi: 10.1016/j.ebiom.2018.08.013. Epub 2018 Aug 14. No abstract available.

16.

Unraveling the Mysteries of the Asthmatic Airway Epithelium.

Loukides S, Bakakos P.

Am J Respir Cell Mol Biol. 2018 Jul;59(1):9-10. doi: 10.1165/rcmb.2018-0040ED. No abstract available.

PMID:
29957048
17.

The self-reported prevalence and disease burden of asthma in Greece.

Kourlaba G, Bakakos P, Loukides S, Vellopoulou K, Solakidi A, Maniadakis N.

J Asthma. 2019 May;56(5):478-497. doi: 10.1080/02770903.2018.1471704. Epub 2018 Jun 22.

PMID:
29718784
18.

Acrometastasis due to lung adenocarcinoma.

Apollonatou V, Loukides S, Papaioannou AI, Papiris S.

Adv Respir Med. 2018;86(2):97-100. doi: 10.5603/ARM.2018.0013.

19.

Falsely Elevated CA 15-3 Levels in Ovarian Sarcoidosis with Peritoneal Involvement and Ascites.

Tsiodras S, Gouloumi AR, Tsakiraki Z, Chrelias G, Chrelias C, Loukides S, Panayiotides I.

Case Rep Obstet Gynecol. 2018 Jan 22;2018:2039730. doi: 10.1155/2018/2039730. eCollection 2018.

20.

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Petta V, Loukides S, Kostikas K, Papaioannou AI, Papatheodorou G, Cholidou K, Tomos I, Papiris S, Koulouris NG, Bakakos P.

J Thorac Dis. 2018 Feb;10(2):740-748. doi: 10.21037/jtd.2018.01.45.

21.

An algorithmic approach for the treatment of severe uncontrolled asthma.

Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M.

ERJ Open Res. 2018 Mar 6;4(1). pii: 00125-2017. doi: 10.1183/23120541.00125-2017. eCollection 2018 Jan. Review.

22.

Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation.

Papaioannou AI, Konstantelou E, Papaporfyriou A, Bartziokas K, Spathis A, Bakakos P, Loukides S, Koulouris N, Papiris S, Kostikas K.

Lung. 2018 Apr;196(2):201-205. doi: 10.1007/s00408-018-0099-5. Epub 2018 Feb 14.

PMID:
29445934
23.

Targeted anti-IL-13 therapies in asthma: current data and future perspectives.

Ntontsi P, Papathanassiou E, Loukides S, Bakakos P, Hillas G.

Expert Opin Investig Drugs. 2018 Feb;27(2):179-186. doi: 10.1080/13543784.2018.1427729. Epub 2018 Jan 19. Review.

PMID:
29334288
24.

Ability of using different dry powder inhalers during COPD exacerbations.

Papaioannou AI, Herodotou Y, Tomos I, Apollonatou V, Verykokou G, Papathanasiou E, Manali ED, Loukides S, Papiris SA.

Pulm Pharmacol Ther. 2018 Feb;48:211-216. doi: 10.1016/j.pupt.2017.12.007. Epub 2017 Dec 19.

PMID:
29277688
25.

Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms.

Ntontsi P, Bakakos P, Papathanasiou E, Tsilogianni Z, Kostikas K, Hillas G, Papatheodorou G, Koulouris N, Papiris S, Loukides S.

J Breath Res. 2018 Feb 20;12(2):026013. doi: 10.1088/1752-7163/aa9d46.

PMID:
29176061
26.

Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study.

Papaioannou AI, Kostikas K, Papaporfyriou A, Angelakis L, Papathanasiou E, Hillas G, Mazioti A, Bakakos P, Koulouris N, Papiris S, Loukides S.

COPD. 2017 Dec;14(6):635-640. doi: 10.1080/15412555.2017.1386644. Epub 2017 Nov 3.

PMID:
29099646
27.

The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer.

Boura P, Grapsa D, Loukides S, Angelidou M, Tsakanika K, Syrigos N, Gkiozos I.

Lung Cancer Manag. 2017 Nov;6(2):55-65. doi: 10.2217/lmt-2016-0018. Epub 2017 Nov 17.

28.

The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.

Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, Loukides S, Papiris S, Koulouris N, Bakakos P.

Cytokine. 2017 Nov;99:281-286. doi: 10.1016/j.cyto.2017.08.005. Epub 2017 Aug 31.

PMID:
28863927
29.

High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations.

Papiris SA, Tomos IP, Karakatsani A, Spathis A, Korbila I, Analitis A, Kolilekas L, Kagouridis K, Loukides S, Karakitsos P, Manali ED.

Cytokine. 2018 Feb;102:168-172. doi: 10.1016/j.cyto.2017.08.019. Epub 2017 Aug 25.

PMID:
28847533
30.

Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.

Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N, Xanthos T, Tsekoura D, Hillas G.

Heart Fail Rev. 2017 Nov;22(6):753-763. doi: 10.1007/s10741-017-9646-z. Review.

PMID:
28840400
31.

Serum periostin in patients hospitalized for COPD exacerbations.

Konstantelou E, Papaioannou AI, Loukides S, Bartziokas K, Papaporfyriou A, Papatheodorou G, Bakakos P, Papiris S, Koulouris N, Kostikas K.

Cytokine. 2017 May;93:51-56. doi: 10.1016/j.cyto.2017.05.007. Epub 2017 May 13.

PMID:
28511944
32.

Decreased Serum Sirtuin-1 in COPD.

Yanagisawa S, Papaioannou AI, Papaporfyriou A, Baker JR, Vuppusetty C, Loukides S, Barnes PJ, Ito K.

Chest. 2017 Aug;152(2):343-352. doi: 10.1016/j.chest.2017.05.004. Epub 2017 May 12.

33.

A European Respiratory Society technical standard: exhaled biomarkers in lung disease.

Horváth I, Barnes PJ, Loukides S, Sterk PJ, Högman M, Olin AC, Amann A, Antus B, Baraldi E, Bikov A, Boots AW, Bos LD, Brinkman P, Bucca C, Carpagnano GE, Corradi M, Cristescu S, de Jongste JC, Dinh-Xuan AT, Dompeling E, Fens N, Fowler S, Hohlfeld JM, Holz O, Jöbsis Q, Van De Kant K, Knobel HH, Kostikas K, Lehtimäki L, Lundberg J, Montuschi P, Van Muylem A, Pennazza G, Reinhold P, Ricciardolo FLM, Rosias P, Santonico M, van der Schee MP, van Schooten FJ, Spanevello A, Tonia T, Vink TJ.

Eur Respir J. 2017 Apr 26;49(4). pii: 1600965. doi: 10.1183/13993003.00965-2016. Print 2017 Apr.

34.

Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.

Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S.

Postgrad Med. 2017 Aug;129(6):598-604. doi: 10.1080/00325481.2017.1321945. Epub 2017 Apr 28.

PMID:
28427296
35.

Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach.

Souliotis K, Kousoulakou H, Hillas G, Bakakos P, Toumbis M, Loukides S, Vassilakopoulos T.

Front Public Health. 2017 Apr 5;5:67. doi: 10.3389/fpubh.2017.00067. eCollection 2017.

36.

Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes.

Ntontsi P, Loukides S, Bakakos P, Kostikas K, Papatheodorou G, Papathanassiou E, Hillas G, Koulouris N, Papiris S, Papaioannou AI.

Allergy. 2017 Nov;72(11):1761-1767. doi: 10.1111/all.13184. Epub 2017 May 11.

PMID:
28407269
37.

The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics.

Konstantellou E, Loukides S, Ntontsi P, Papathanasiou E, Kostikas K, Paptheodorou G, Hillas G, Papiris S, Koulouris NG, Bakakos P.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1129-1131.e3. doi: 10.1016/j.jaip.2017.03.005. Epub 2017 Apr 7. No abstract available.

PMID:
28396112
38.

Asthma phenotypes in children and stratified pharmacological treatment regimens.

Iordanidou M, Loukides S, Paraskakis E.

Expert Rev Clin Pharmacol. 2017 Mar;10(3):293-303. doi: 10.1080/17512433.2017.1271322. Epub 2016 Dec 20. Review.

PMID:
27936975
39.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

40.

Severe asthma: anti-IgE or anti-IL-5?

Papathanassiou E, Loukides S, Bakakos P.

Eur Clin Respir J. 2016 Nov 7;3:31813. doi: 10.3402/ecrj.v3.31813. eCollection 2016. Review.

41.

Activin A and follistatin in patients with asthma. Does severity make the difference?

Papaporfyriou A, Bakakos P, Kostikas K, Papatheodorou G, Hillas G, Trigidou R, Katafigiotis P, Koulouris NG, Papiris SA, Loukides S.

Respirology. 2017 Apr;22(3):473-479. doi: 10.1111/resp.12937. Epub 2016 Nov 2.

PMID:
27807906
42.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Nov;46(11):1498. doi: 10.1111/cea.12825. No abstract available.

PMID:
27790845
43.

Quantitative computed tomography: what does airway obstruction look-like?

Kallieri M, Papaioannou AI, Kostikas K, Bakakos P, Loukides S.

J Thorac Dis. 2016 Sep;8(9):E1044-E1046. No abstract available.

44.

Predictors of future exacerbation risk in patients with asthma.

Papaioannou AI, Kostikas K, Bakakos P, Papaporfyriou A, Konstantellou E, Hillas G, Papatheodorou G, Koulouris NG, Papiris S, Loukides S.

Postgrad Med. 2016 Sep;128(7):687-92. doi: 10.1080/00325481.2016.1220807. Epub 2016 Aug 17.

PMID:
27494758
45.

Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE).

Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Spathis A, Mazioti A, Tomos I, Papanikolaou I, Loukides S, Chainis K, Karakitsos P, Griese M, Papiris S.

PLoS One. 2016 Jun 23;11(6):e0157789. doi: 10.1371/journal.pone.0157789. eCollection 2016.

46.

Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?

Tsilogianni Z, Ntontsi P, Papaioannou AI, Bakakos P, Loukides S.

Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):1-9. doi: 10.1007/s00005-016-0407-9. Epub 2016 Jun 8. Review.

PMID:
27271573
47.

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.

Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A.

Drug Target Insights. 2016 May 22;10:9-12. doi: 10.4137/DTI.S31565. eCollection 2016.

48.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Jul;46(7):923-31. doi: 10.1111/cea.12729. Epub 2016 May 3. Erratum in: Clin Exp Allergy. 2016 Nov;46(11):1498.

PMID:
26990030
49.

Duration of Hospitalization and Lung Function Deterioration as Predictors of Future Chronic Obstructive Pulmonary Disease Exacerbations.

Papaioannou AI, Bartziokas K, Papiris S, Loukides S, Kostikas K.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):698-700. doi: 10.1164/rccm.201511-2141LE. No abstract available.

PMID:
26977972
50.

Changes in BODE Quartiles After Pulmonary Rehabilitation Do Not Predict 2-Year Survival in Patients With COPD.

Kavoura P, Kostikas K, Tselebis A, Bratis D, Kosmas E, Alchanatis M, Koulouris NG, Bakakos P, Loukides S.

J Cardiopulm Rehabil Prev. 2016 Jan-Feb;36(1):62-7. doi: 10.1097/HCR.0000000000000157.

PMID:
26629865

Supplemental Content

Loading ...
Support Center